Navigation Links
Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010
Date:2/19/2010

GALWAY, Ireland, Feb. 19 /PRNewswire/ -- Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented "Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS & OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.

The newest addition to the Sideguard portfolio, the Sideguard 3.25, was implanted successfully in a live case performed by Ralf Mueller, MD, Siegburg, Germany. According to Dr. Mueller, "We implanted the Sideguard 3.25 stent together with a 3,0mm DES in a Medina 0,1,1 LAD/D1 stenosis.  Positioning was easy and precise and IVUS demonstrated excellent scaffolding at the bifurcation. The use of the Sideguard device made this bifurcation intervention easy and predictable with an optimal acute result."

Martin B. Leon, MD, Founder & Director of Transcatheter Cardiovascular Therapeutics (TCT) and Scientific Advisory Board member of Cappella assisted with the case. Dr. Leon expressed his satisfaction with the device, "It was the first time I used the 3.25 & I was very pleased with the outcome of the case."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc.  For more information, see: www.cappella-med.com.

SOURCE Cappella Inc.

Back to top

RELATED LINKS
http://www.cappella-med.com

'/>"/>

SOURCE Cappella Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Eamonn Hobbs Joins the Board of Directors at Cappella
2. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
3. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
4. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
5. PLAN C Agency Promotes Hepatitis B Awareness Through B HERE
6. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
7. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
8. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
9. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
10. Robbins & Myers Announces Regular Quarterly Cash Dividend
11. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 According to a new ... Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market was valued at ... growing at a CAGR of 3.6% during the forecast period. ... ... Market Research Logo ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ Million. ... , Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... ... very strong with a total of 97 drug candidates. Pharma giant such ... involved in the development of the IPF therapeutics. The IPF pipeline comprised ... 15 are in Phase II stage, 12 are in Phase I stage, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces distribution of ... current obstacles facing infection prevention and offer strategies for the health care community ... , The print component of “Fighting Infection” is distributed within the Friday, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... According to ... score is invalid because it does not obey the rules Congress has directed the ... equivalent jobs, which the GOP reform would restore. Yet, it estimates a reduction in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, Cassie ... Litigation seminar in Chicago, Illinois. She will present on: , Filing Benefit ... under ERISA involve claims for long-term disability benefits. This session will address ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... enhancements, upgrading their training and leads programs. , In February, 2017, Empower Brokerage ... sales agents, Performance Partners is designed to teach how to maximize their sales ...
Breaking Medicine News(10 mins):